NEW YORK(GenomeWeb) – Exosome Diagnostics said today that it has raised $17.6 million in a second Series B financing round.

Combined with funds from a first round, the firm said it has raised a total of $44.7 million in its Series B overall.

Participating investors in the second round included Forbion Capital Partners, NGN Capital, Arcus Ventures, Tiger Management, and CD Ventures, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.